Shattuck Labs, Inc. Tax Withholding Paid on Stock Awards
Shattuck Labs, Inc. (STTK) reported Tax Withholding Paid on Stock Awards of $269.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-11
- Shattuck Labs, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $7.00K.
- Shattuck Labs, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $262.00K, a 303.08% increase year-over-year.
- Shattuck Labs, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00.
- Shattuck Labs, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Shattuck Labs, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $65.00K, a 85.59% decline from fiscal 2024.
- Shattuck Labs, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $451.00K, a 750.94% increase from fiscal 2023.
- Shattuck Labs, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $53.00K.
- Shattuck Labs, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $0.00.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $269.00K 10-Q · filed 2026-08-11 | $269.00K derived: sum of 3 quarters · filed 2026-08-11 | $269.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $262.00K 10-Q · filed 2026-05-07 | $262.00K derived: sum of 2 quarters · filed 2026-05-07 | $262.00K derived: sum of 3 quarters · filed 2026-05-07 | $262.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $65.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $65.00K 10-Q · filed 2025-11-06 | $65.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $65.00K 10-Q · filed 2026-08-11 | $65.00K derived: sum of 3 quarters · filed 2026-08-11 | $69.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $65.00K 10-Q · filed 2026-05-07 | $65.00K derived: sum of 2 quarters · filed 2026-05-07 | $69.00K derived: sum of 3 quarters · filed 2026-05-07 | $79.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.00K derived: sum of 2 quarters · filed 2026-03-05 | $14.00K derived: sum of 3 quarters · filed 2026-03-05 | $451.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.00K derived: sum of 2 quarters · filed 2025-11-06 | $451.00K 10-Q · filed 2025-11-06 | $465.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $447.00K 10-Q · filed 2025-08-14 | $461.00K derived: sum of 3 quarters · filed 2025-08-14 | $461.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $437.00K 10-Q · filed 2025-05-01 | $451.00K derived: sum of 2 quarters · filed 2025-05-01 | $451.00K derived: sum of 3 quarters · filed 2025-05-01 | $451.00K derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $14.00K derived: sum of 2 quarters · filed 2025-03-27 | $14.00K derived: sum of 3 quarters · filed 2025-03-27 | $53.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $39.00K 10-Q · filed 2024-11-14 | $39.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $39.00K 10-Q · filed 2024-08-01 | $39.00K derived: sum of 3 quarters · filed 2024-08-01 | $39.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $39.00K 10-Q · filed 2024-05-02 | $39.00K derived: sum of 2 quarters · filed 2024-05-02 | $39.00K derived: sum of 3 quarters · filed 2024-05-02 | $39.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |